CO5700712A2 - Prevencion y tratamiento de la enfermedad de alzheimer - Google Patents

Prevencion y tratamiento de la enfermedad de alzheimer

Info

Publication number
CO5700712A2
CO5700712A2 CO05056010A CO05056010A CO5700712A2 CO 5700712 A2 CO5700712 A2 CO 5700712A2 CO 05056010 A CO05056010 A CO 05056010A CO 05056010 A CO05056010 A CO 05056010A CO 5700712 A2 CO5700712 A2 CO 5700712A2
Authority
CO
Colombia
Prior art keywords
alkyl
propyl
butyl
ethyl
bile acid
Prior art date
Application number
CO05056010A
Other languages
English (en)
Spanish (es)
Inventor
Thierry Canton
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of CO5700712A2 publication Critical patent/CO5700712A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
CO05056010A 2002-12-12 2005-06-09 Prevencion y tratamiento de la enfermedad de alzheimer CO5700712A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
CO5700712A2 true CO5700712A2 (es) 2006-11-30

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05056010A CO5700712A2 (es) 2002-12-12 2005-06-09 Prevencion y tratamiento de la enfermedad de alzheimer

Country Status (22)

Country Link
EP (1) EP1572174A1 (lt)
JP (1) JP2006514063A (lt)
KR (1) KR20050084250A (lt)
CN (1) CN1726016A (lt)
AR (1) AR042354A1 (lt)
AU (1) AU2003296802A1 (lt)
BR (1) BR0317280A (lt)
CA (1) CA2507945A1 (lt)
CO (1) CO5700712A2 (lt)
FR (1) FR2848452B1 (lt)
HR (1) HRP20050534A2 (lt)
MA (1) MA27500A1 (lt)
MX (1) MXPA05005556A (lt)
NO (1) NO20053341L (lt)
NZ (1) NZ540496A (lt)
PE (1) PE20040770A1 (lt)
PL (1) PL377110A1 (lt)
RS (1) RS20050420A (lt)
RU (1) RU2005121909A (lt)
TW (1) TW200503707A (lt)
WO (1) WO2004062652A1 (lt)
ZA (1) ZA200504656B (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
NZ546887A (en) 2003-11-03 2009-04-30 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
JP4996926B2 (ja) 2004-02-05 2012-08-08 プロビオドルグ エージー グルタミニルシクラーゼの新規の阻害剤
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
PL2157973T3 (pl) * 2007-05-22 2015-12-31 Otsuka Pharma Co Ltd Lek zawierający pochodną karbostyrylu i donepezil do leczenia choroby Alzheimera
MX363161B (es) * 2011-10-28 2019-03-13 Lumena Pharmaceuticals Inc Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica.
US20140243281A1 (en) * 2011-10-28 2014-08-28 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
CA2104594C (en) * 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
JP2001508762A (ja) * 1996-06-27 2001-07-03 ジー．ディー．サール アンド カンパニー 架橋した外殻領域および内部芯領域を有する両親媒性コポリマーからなり、医薬およびその他の用途に有用な粒子
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
ES2257824T3 (es) * 1998-01-28 2006-08-01 Warner-Lambert Company Llc Metodo para tratar la enfermedad de alzheimer.
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
WO2001056579A1 (en) * 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
RS20050420A (en) 2007-04-10
PE20040770A1 (es) 2004-12-10
HRP20050534A2 (en) 2006-11-30
FR2848452A1 (fr) 2004-06-18
BR0317280A (pt) 2005-11-08
CA2507945A1 (fr) 2004-07-29
NO20053341D0 (no) 2005-07-08
MA27500A1 (fr) 2005-08-01
AR042354A1 (es) 2005-06-15
NO20053341L (no) 2005-09-07
MXPA05005556A (es) 2005-07-26
JP2006514063A (ja) 2006-04-27
NZ540496A (en) 2008-04-30
FR2848452B1 (fr) 2007-04-06
RU2005121909A (ru) 2006-01-20
PL377110A1 (pl) 2006-01-23
ZA200504656B (en) 2006-08-30
WO2004062652A1 (fr) 2004-07-29
TW200503707A (en) 2005-02-01
CN1726016A (zh) 2006-01-25
KR20050084250A (ko) 2005-08-26
AU2003296802A1 (en) 2004-08-10
EP1572174A1 (fr) 2005-09-14

Similar Documents

Publication Publication Date Title
CO5700712A2 (es) Prevencion y tratamiento de la enfermedad de alzheimer
BR0312999A (pt) Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
UY28674A1 (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
BR0010555A (pt) Inibidores de neuraminidases
WO2006028269A3 (en) Thiazole derivatives having vap-1 ihibitory activity
HUP0301427A2 (hu) Fotokemoterápiában alkalmazható fotoszenzitizáló, 5-aminolevulinsavészterek azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
TW200420549A (en) Thiazole derivatives
CO5611108A2 (es) Benzazoles sustituidos y su aplicacion como inhibidores quinasa raf
NZ580226A (en) Dimer compounds as inhibitors of iap
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
WO2008002573A3 (en) Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
CO6241190A2 (es) Compuestos para inhibicion enzimatica
ATE427941T1 (de) Thiazolderivate mit vap-1-hemmender wirkung
DE60130023D1 (de) Behandlung der nebenwirkungen von statinen
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
MX2009008779A (es) Composicion farmacéutica que comprende derivado de pirazina y método para usar el derivado de pirazina en combinación.
TWI265929B (en) Triazinyl derivatives for inhibiting the production of IL-12
CO5031242A1 (es) Derivados de cromanona y tiocromanona, proceso para su preparacion y composicion farmaceutica que los comprende
GEP20125548B (en) New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them
MX2023001298A (es) Combinaciones para el tratamiento de cancer.
HK1127476A1 (en) Pyrazolopyrimidine derivative
AR038624A1 (es) Un procedimiento para preparar un derivado de fenilalanina e intermediarios del mismo
TW200745048A (en) Novel benzimidazole and benzothiazole derivatives, preparation process therefor, application thereof as medicaments, pharmaceutical compositions and novel use especially as CMET inhibitors
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger
AR035285A1 (es) Formulaciones en combinacion de derivados de1,4-benzotiepina-1,1-dioxido con otras sustancias activas, y su utilizacion.

Legal Events

Date Code Title Description
FC Application refused